Kairos Pharma Ltd./$KAPA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kairos Pharma Ltd.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
Ticker
$KAPA
Sector
Primary listing
AMEX
Employees
3
Headquarters
Website
KAPA Metrics
BasicAdvanced
$10m
-
-$0.30
-
-
Price and volume
Market cap
$10m
52-week high
$2.11
52-week low
$0.40
Average daily volume
151k
Financial strength
Current ratio
10.309
Quick ratio
8.527
Profitability
EBITDA (TTM)
-5.836
Management effectiveness
Return on assets (TTM)
-54.78%
Return on equity (TTM)
-93.84%
Valuation
Price to book
1.93
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
-2.504
Free cash flow yield (TTM)
-39.94%
Free cash flow per share (TTM)
-0.191
Growth
Earnings per share change (TTM)
6.18%
3-year earnings per share growth (CAGR)
47.02%
KAPA News
AllArticlesVideos
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
Newsfile Corp·1 week ago
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
Business Wire·2 weeks ago
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kairos Pharma Ltd. stock?
Kairos Pharma Ltd. (KAPA) has a market cap of $10M as of May 20, 2026.
What is the P/E ratio for Kairos Pharma Ltd. stock?
The price to earnings (P/E) ratio for Kairos Pharma Ltd. (KAPA) stock is 0 as of May 20, 2026.
Does Kairos Pharma Ltd. stock pay dividends?
No, Kairos Pharma Ltd. (KAPA) stock does not pay dividends to its shareholders as of May 20, 2026.
When is the next Kairos Pharma Ltd. dividend payment date?
Kairos Pharma Ltd. (KAPA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kairos Pharma Ltd.?
Kairos Pharma Ltd. (KAPA) does not currently have a Beta indicator.